var data={"title":"Testosterone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Testosterone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7027?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=testosterone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Testosterone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=testosterone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Testosterone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9632723\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary exposure (transdermal gel, transdermal solution):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Virilization has been reported in children who were secondarily exposed to topical testosterone gel and solution. Children should avoid contact with unwashed or unclothed application sites in men using topical testosterone.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Advise patients to strictly adhere to recommended instructions for use.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pulmonary oil microembolism (testosterone undecanoate):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious pulmonary oil microembolism (POME) reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Following each injection, observe patients in the health care setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risks of serious POME reactions and anaphylaxis, testosterone undecanoate is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) called the Aveed REMS Program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225996\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Androderm;</li>\n      <li>AndroGel;</li>\n      <li>AndroGel Pump;</li>\n      <li>Aveed;</li>\n      <li>Axiron [DSC];</li>\n      <li>Depo-Testosterone;</li>\n      <li>EC-RX Testosterone;</li>\n      <li>First-Testosterone MC [DSC];</li>\n      <li>First-Testosterone [DSC];</li>\n      <li>Fortesta;</li>\n      <li>Natesto;</li>\n      <li>Striant;</li>\n      <li>Testim;</li>\n      <li>Testopel;</li>\n      <li>Vogelxo;</li>\n      <li>Vogelxo Pump</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225997\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Andriol;</li>\n      <li>Androderm;</li>\n      <li>AndroGel;</li>\n      <li>Axiron;</li>\n      <li>Delatestryl;</li>\n      <li>Depo-Testosterone;</li>\n      <li>Natesto;</li>\n      <li>Testim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226028\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Androgen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226000\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In adult men with androgen deficiency syndromes (eg, hypogonadism), withhold initial treatment with hematocrit &gt;50% (discontinue therapy if hematocrit exceeds 54%), hyperviscosity, untreated obstructive sleep apnea, uncontrolled severe heart failure, or with severe untreated BPH with IPSS symptom score &gt;19 (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer (females):</b> <i>IM (testosterone enanthate):</i> 200 to 400 mg every 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delayed puberty (males):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM (testosterone enanthate):</i> 50 to 200 mg every 2 to 4 weeks for a limited duration (eg, 4 to 6 months)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pellet (for subcutaneous implantation):</i> 150 to 450 mg every 3 to 6 months. Dosing is generally at the lower range for a limited duration (eg, 4 to 6 months).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypogonadism (primary) or hypogonadism (hypogonadotropic) (males):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM (testosterone enanthate or testosterone cypionate):</i> 50 to 400 mg every 2 to 4 weeks (manufacturer's labeling); 75 to 100 mg/week or 150 to 200 mg every 2 weeks (Endocrine Society [Bhasin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM (Testosterone undecanoate): </i>Initial dose: 750 mg, followed by 750 mg administered 4 weeks later, then 750 mg administered every 10 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal: Testosterone gel:</i> Natesto: 11 mg (2 pump actuations; 1 actuation per nostril) intranasally 3 times daily (6 to 8 hours apart). Total daily dose: 33 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose adjustment based on testosterone levels:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Less than normal range: Consider alternative treatment if consistently &lt;300 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Greater than normal range: Discontinue if consistently &gt;1050 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral: (Andriol [Canadian product]): </i>Initial: 120 to 160 mg daily in 2 divided doses for 2 to 3 weeks; adjust according to individual response and/or testosterone levels; usual maintenance dose: 40 to 120 mg daily (in divided doses)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pellet (for subcutaneous implantation):</i> 150 to 450 mg every 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Topical:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Buccal: 30 mg twice daily (every 12 hours) applied to the gum region above the incisor tooth. Discontinue if serum testosterone concentrations are consistently outside of the normal range.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AndroGel 1%: 50 mg applied once daily in the morning to the shoulder and upper arms, or abdomen. Dosage range: 50 to 100 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dose adjustment based on testosterone levels: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Less than normal range: Increase dose from 50 mg to 75 mg or from 75 mg to 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Greater than normal range: Decrease dose. Discontinue if consistently above normal at 50 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AndroGel 1.62%: 40.5 mg applied once daily in the morning to the shoulder and upper arms. Dosage range: 20.25 mg to 81 mg daily; maximum: 81 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dose adjustment based on testosterone levels: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;750 ng/dL: Decrease dose by 20.25 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;350 ng/dL to &le;750 ng/dL: Maintain current dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;350 ng/dL: Increase dose by 20.25 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fortesta: 40 mg once daily in the morning. Apply to the thighs. Dosing range: 10 to 70 mg daily; maximum: 70 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dose adjustment based on serum testosterone levels:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;2500 ng/dL: Decrease dose by 20 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;1250 to &lt;2500 ng/dL: Decrease dose by 10 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;500 and &lt;1250 ng/dL: Maintain current dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;500 ng/dL: Increase dose by 10 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Testim: 50 mg applied once daily (preferably in the morning) to the shoulder and upper arms. If testosterone concentrations are less than the normal range, dosage may be increased from 50 mg to 100 mg once daily; maximum: 100 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Vogelxo: 50 mg applied once daily to the shoulder and/or upper arms. Dosage may be increased to a maximum of 100 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dose adjustment based on testosterone levels:</i> Less than normal range: Increase dose from 50 mg to 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution (Axiron): 60 mg once daily (dosage range: 30 to 120 mg daily). Apply to the axilla at the same time each morning.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dose adjustment based on serum testosterone levels:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;1050 ng/dL: Decrease 60 mg daily dose to 30 mg daily; if levels &gt;1050 ng/dL persist after dose reduction, discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;300 ng/dL: Increase 60 mg daily dose to 90 mg daily, or increase 90 mg daily dose to 120 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal system (Androderm):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 4 mg daily (as one 4 mg/day patch; do <b>not</b> use two 2 mg/day patches)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Dose adjustment based on testosterone levels:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;930 ng/dL:  Decrease dose to 2 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">400 to 930 ng/dL: Continue 4 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;400 ng/dL: Increase dose to 6 mg daily(as one 4 mg/day and one 2 mg/day patch)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Dosing conversion:</b> The 2.5 mg/day and the 5 mg/day patches have been discontinued in the US; patients may be switched from the 2.5 mg/day patch, 5 mg/day patch, or the combination (ie, 7.5 mg/day) as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">From 2.5 mg/day patch to 2 mg/day patch</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">From 5 mg/day patch to 4 mg/day patch</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">From 7.5 mg daily (one 2.5 mg/day and one 5 mg/day patch) to 6 mg daily (one 2 mg/day and one 4 mg/day patch)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Patch change should occur at the next scheduled dosing. Measure early morning testosterone concentrations ~2 weeks after switching therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226019\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=testosterone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Testosterone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Delayed puberty (adolescent males):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">\n      <i>IM (testosterone enanthate):</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Pellet (for subcutaneous implantation):</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypogonadism (primary) or hypogonadism (hypogonadotropic) (adolescent males):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>IM (testosterone enanthate or testosterone cypionate):</i> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Pellet (for subcutaneous implantation):</i> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226001\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11386628\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). May enhance edema formation. Testosterone cypionate is contraindicated in serious renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226002\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments  provided in the manufacturer&rsquo;s labeling (has not been studied). May enhance edema formation. Testosterone cypionate is contraindicated in serious hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225970\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EC-RX Testosterone: 0.2% (30 g, 60 g); 0.4% (30 g, 60 g); 10% (30 g, 60 g); 20% (30 g, 60 g) [contains cetearyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Testosterone MC: 2% (60 g [DSC]) [contains benzyl alcohol, sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Natesto: 5.5 mg/actuation (7.32 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AndroGel: 25 mg/2.5 g (1%) (2.5 g) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AndroGel: 20.25 mg/1.25 g (1.62%) (1.25 g); 40.5 mg/2.5 g (1.62%) (2.5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AndroGel: 50 mg/5 g (1%) (5 g) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AndroGel Pump: 20.25 mg/actuation (1.62%) (75 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AndroGel Pump: 12.5 mg/actuation (1%) (75 g [DSC]) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortesta: 10 mg/actuation (2%) (60 g) [odorless; contains propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Testim: 50 mg/5 g (1%) (5 g) [contains alcohol, usp, propylene glycol, tromethamine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vogelxo: 50 mg/5 g (1%) (5 g) [contains alcohol, usp, tromethamine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vogelxo Pump: 12.5 mg/actuation (1%) (75 g) [contains alcohol, usp, tromethamine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/2.5 g (1%) (2.5 g); 10 mg/actuation (2%) (60 g); 12.5 mg/actuation (1%) (75 g); 50 mg/5 g (1%) (5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous, Buccal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Striant: 30 mg (60 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Testosterone: 2% (60 g [DSC]) [contains benzyl alcohol, butylated hydroxytoluene (bht), petrolatum, sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch 24 Hour, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Androderm: 2 mg/24 hr (1 ea, 60 ea); 4 mg/24 hr (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pellet, Implant: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Testopel: 75 mg (10 ea, 100 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pellet, Implant [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12.5 mg (1 ea [DSC]); 25 mg (1 ea [DSC]); 37.5 mg (1 ea [DSC]); 50 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Axiron: 30 mg/actuation (90 mL [DSC]) [contains isopropyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg/actuation (90 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular, as cypionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depo-Testosterone: 100 mg/mL (10 mL); 200 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, benzyl benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (10 mL); 200 mg/mL (1 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular, as enanthate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular, as undecanoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aveed: 750 mg/3 mL (3 mL) [contains benzyl benzoate, castor oil (ricine oil)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225954\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040041\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">EC-RX Testosterone, First-Testosterone MC cream, and First-Testosterone ointment are compounding kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950983\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, gelatin, as undecanoate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Andriol: 40 mg (10s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226030\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-III</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9632804\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AndroGel 1%: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM188474.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQuw1KMRbFiKb4zJVB1uDxfQ==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM188474.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AndroGel 1.62%: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM255313.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68jm7Dv9/7owpaAZZNmx+sTQ==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM255313.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aveed: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM403061.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gin2KVMRAvBTcNVHD24dJKVQ==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM403061.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Axiron: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022504s016lbl.pdf#page=15&amp;token=H8MAqoB8iYeidKz1pDiZeUZ6bj+l/qP1b+efeS1b4JeDYKJA3gRa7dqrDus1XxxkOK4HcnOMSvnTOth6Fv+t8tDq5yRIyzFTs1F0dfrLzYPWLwIKRsVVKB68Xj7/UbGP&amp;TOPIC_ID=9981\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022504s016lbl.pdf#page=15</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fortesta: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM239932.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68vrchydyQb+hJnPoRGxTJ2w==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM239932.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Testim: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM188475.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQ0uJkBCrE2ZK0ajWDkrogNQ==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM188475.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Testosterone Gel (Perrigo): <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM294248.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68PCEhIOh/d06erplSvhD+hA==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM294248.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Testosterone Gel (Teva): <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM403065.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giU164ebp92vRqWrWNUQkpww==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM403065.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vogelxo: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM448177.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gifa4+SJqjhGgJTqCBHGrrKQ==&amp;TOPIC_ID=9981\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM448177.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225974\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer by deep IM injection into the gluteal muscle. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Testosterone undecanoate: Inject into the gluteus medius; alternate injection between left and right buttock. Avoid intravascular injection, may lead to pulmonary oil microembolism; avoid the superior gluteal arteries and sciatic nerve.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intranasal gel (Natesto): Administer intranasally 3 times daily,  6 to 8 hours apart, preferably at the same time each day. Prime pump prior to first use by inverting then depressing pump 10 times (discard this portion of product into sink). Blow nose prior to application. To administer the dose, insert actuator into nostril until pump reaches base of nose; tilt so the tip is in contact with the lateral wall of nostril. Depress slowly until pump stops, then remove from nose while wiping tip to transfer gel to lateral side of nostril.  Following administration, press on the nostrils at a point just below the bridge of the nose and lightly massage. Refrain from blowing nose or sniffing for 1 hour after administration. If gel gets on hands, wash with warm soap and water. Temporarily discontinue with episodes of severe rhinitis; if severe rhinitis symptoms persist consider an alternative therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral, buccal application (Striant): One mucoadhesive for buccal application (buccal system) should be applied to a comfortable area above the incisor tooth twice daily. Gently push the curved side against the upper gum. Hold buccal system firmly in place by pushing down on outside of the upper lip for 30 seconds to ensure adhesion. The buccal system should adhere to gum until it is removed. Rotate to alternate sides of mouth with each application. If the buccal system falls out, replace with a new system. If the system falls out within the first 8 hours of dosing, replace with a new buccal system and continue for a total of 12 hours from the placement of the first system. If the system falls out of position after 8 hours of dosing, a new buccal system should be applied and it may remain in place for 12 hours, then continue with the next regularly scheduled dosing. System will soften and mold to shape of gum as it absorbs moisture from mouth. Do not chew or swallow the buccal system. The buccal system will not dissolve; gently remove by sliding downwards from gum; avoid scratching gum. Remove prior to routine morning and evening oral care, prior to application of new system.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral, capsule (Andriol [Canadian product]): Administer with meals. Should be swallowed whole; do not crush or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subcutaneous implant (Testopel): Using strict sterile technique, must be surgically implanted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch (Androderm): Apply to skin immediately upon removal from the protective pouch. Apply at the same time each night to  clean, dry area of skin on the back, abdomen, upper arms, or thigh. Do not apply to bony areas or parts of the body that are subject to prolonged pressure while sleeping or sitting. Do not apply to oily, damaged or irritated skin. Do not apply to the scrotum. Rotate administration sites, allowing 7 days between applying to the same site. Avoid showering, washing the site, or swimming for &ge;3 hours after application. Following patch removal, mild skin irritation may be treated with OTC hydrocortisone cream. A small amount of triamcinolone acetonide 0.1% cream may be applied under the system to decrease irritation; do not use ointment (triamcinolone ointment decreases testosterone absorption). Dispose of any used or unused patches by folding adhesive ends together, replace in pouch or sealed container and discard properly in trash away from children and pets. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Topical gel and solution:  Alcohol-based gels and solutions are flammable; avoid fire, flames, or smoking until dry. Testosterone may be transferred to another person following skin-to-skin contact with the application site. Strict adherence to application instructions is needed in order to decrease secondary exposure. Thoroughly wash hands after application and cover application site with clothing (ie, shirt) once gel or solution has dried, or clean application site thoroughly with soap and water prior to contact in order to minimize transfer. In addition to skin-to-skin contact, secondary exposure has also been reported following exposure to secondary items (eg, towel, shirt, sheets). If secondary exposure occurs, the other person should thoroughly wash the skin with soap and water as soon as possible. The application sites and doses of these products are not interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AndroGel 1%: Apply at the same time each morning to clean, dry, intact skin to an area of the shoulder, upper arms, and/or abdomen that will be covered by a short sleeve t-shirt. Do not apply to other parts of the body such as the genitals, chest, back, axillae, or knees. Upon opening the packet(s), the entire contents should be squeezed into the palm of the hand and immediately applied to the application site(s). Alternatively, a portion may be squeezed onto palm of hand and applied, repeating the process at the same or other site until entire packet has been applied. Avoid swimming, showering or washing the application site for &ge;5 hours following application. Cover application site with clothing (eg t-shirt) once the gel has dried. When using the multidose pump, prime pump 3 times (and discard this portion of product) prior to initial use. Each actuation delivers 12.5 mg of testosterone (4 actuations = 50 mg; 6 actuations = 75 mg; 8 actuations = 100 mg). When using the pump, the gel may be delivered into the palm of the hand prior to application or applied directly to the application site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">AndroGel 1.62%: Apply at the same time each morning to clean, dry, intact skin to an area of the shoulder and upper arms that will be covered by a short sleeve t-shirt. Do not apply to other parts of the body such as the abdomen, genitals, chest, axillae, or knees. Upon opening the packet(s), the entire contents should be squeezed into the palm of the hand and immediately applied to the application site(s). Alternatively, a portion may be squeezed onto palm of hand and applied, repeating the process at the same or other site until entire packet has been applied. Avoid swimming, showering or washing the application site for &ge;2 hours following application. Cover application site with clothing (eg t-shirt) once the gel has dried. When using the multidose pump, prime pump 3 times (and discard this portion of product) prior to initial use. Each actuation delivers 20.25 mg of testosterone (2 actuations = 40.5 mg; 3 actuations = 60.75 mg; 4 actuations = 81 mg). When using the pump, the gel may be delivered into the palm of the hand prior to application or applied directly to the application site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Axiron: Apply using the applicator to clean, dry, intact skin on an area of the axilla at the same time each morning. Do not apply to other parts of the body (eg, abdomen, genitals, shoulders, upper arms). Avoid washing the site or swimming for 2 hours after application. Prior to first use, prime the applicator pump by depressing it 3 times (discard this portion of the product). After priming, position the nozzle over the applicator cup and depress pump fully one time; ensure liquid enters cup. Each pump actuation delivers testosterone 30 mg. No more than 30 mg (one pump) should be added to the cup at one time. The total dose should be divided between axilla (example, 30 mg/day: apply to one axilla only; 60 mg/day: apply 30 mg to each axilla; 90 mg/day: apply 30 mg to each axilla, allow to dry, then apply an additional 30 mg to one axilla; etc). To apply dose, keep applicator upright and wipe into the axilla; if solution runs or drips, use cup to wipe. Do not rub into skin with fingers or hand. If more than one 30 mg dose is needed, repeat process. Apply roll-on or stick antiperspirants or deodorants prior to testosterone. Once application site is dry, cover with clothing. After use, rinse applicator under running water and pat dry with a tissue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Fortesta: Apply to clean dry intact skin once daily in the morning to skin of front and inner thighs. Do not apply to genitals or other parts of the body. Use one finger to rub gel evenly onto skin of each thigh. Avoid showering, washing the site, or swimming for &ge;2 hours after application. Prior to first dose, prime the pump by holding canister upright and fully depressing the pump 8 times (discard this portion of the product). Each pump actuation delivers testosterone 10 mg. The total dose should be divided between thighs (example, 10 mg/day: apply 10 mg to one thigh only; 20 mg/day: apply 10 mg to each thigh; 30 mg/day: apply 20 mg to one thigh and 10 mg to the other thigh; etc). Once application site is dry, cover with clothing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Testim: Apply once daily (preferably in the morning) to clean, dry, intact skin to an area of the shoulder and upper arms that will be covered by a short sleeve t-shirt. Do not apply to the genitals or abdomen. Upon opening the tube, the entire contents should be squeezed into the palm of the hand and immediately applied to the application site(s). Avoid swimming, showering or washing the application site for &ge;2 hours following application. Cover application site with clothing (eg t-shirt) once the gel has dried.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Vogelxo: Apply once daily at the same time each morning to clean dry intact skin to an area of the shoulder and upper arms that will be covered by a short sleeve t-shirt. Do not apply to the genitals or to the abdomen. Upon opening the tube or packet, the entire contents should be squeezed into the palm of the hand and immediately applied to the application site(s). If two doses (testosterone 100 mg) are needed, apply one dose (50 mg) to upper arm and or/shoulder, then apply the second dose (50 mg) to the opposite upper arm and/or shoulder. Avoid showering, washing the site, or swimming for at least 2 hours following application. Cover application site with clothing (eg t-shirt) once the gel has dried. When using the multidose pump, prime pump 3 times by fully depressing the pump mechanism (actuation) and discard this portion of product. Each actuation delivers testosterone 12.5 mg (4 actuations = 50 mg; 8 actuations = 100 mg).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132740\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For IM preparation, double gloves, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) are recommended. Double gloving and a protective gown are required during IM administration. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225973\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic:</b> Injection (enanthate): Secondary treatment in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Use may be considered in premenopausal women with breast cancer who have benefited from oophorectomy and have a hormone-responsive tumor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delayed puberty:</b> Injection (enanthate); pellet: To stimulate puberty in carefully selected males with delayed puberty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypogonadism, hypogonadotropic (congenital or acquired):</b> Buccal; Capsule (oral) [Canadian product]; Gel (nasal, transdermal); Injection (cypionate, enanthate, undecanoate); Patch (transdermal); Pellet; Solution (transdermal): Gonadotropin or luteinizing hormone-releasing hormone deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypogonadism, primary (congenital or acquired):</b> Buccal; Capsule (oral) [Canadian product]; Gel (nasal, transdermal); Injection (cypionate, enanthate, undecanoate); Patch (transdermal); Pellet; Solution (transdermal): Treatment of testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Safety and efficacy in men with age-related hypogonadism (or late-onset hypogonadism) has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226035\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Testosterone may be confused with testolactone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">AndroGel 1% may be confused with AndroGel 1.62%</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bio-T-Gel may be confused with T-Gel</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Testosterone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its potential for cardiac problems; use is contraindicated in men with prostate cancer. Avoid unless testosterone is used for confirmed hypogonadism with clinical symptoms (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225961\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin blister (application site; transdermal: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Prostate specific antigen increase (&le;6%; topical: &le;18%; buccal: 2%), benign prostatic hypertrophy (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application-site pruritus (transdermal: 17% to 37%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (&le;3%; buccal: &le;8%; intranasal: &gt;6%), peripheral vascular disease (transdermal: &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Emotional lability (buccal: &le;8%; intramuscular, topical: &le;3%), anosmia (intranasal: 6%; buccal: 1%), altered sense of smell (intranasal: 5% to &gt;6%; topical: 1%), headache (&le;4%), procedural pain (intramuscular, intranasal: 4%), depression (&le;3%), nervousness (&le;3%), abnormality in thinking (transdermal: &lt;3%), anxiety (&lt;3%), body pain (transdermal: &lt;3%), chills (transdermal: &lt;3%), confusion (transdermal: &lt;3%), fatigue (&lt;3%), paresthesia (&lt;3%), vertigo (transdermal: &lt;3%), irritability (intramuscular: 2%), insomnia (intramuscular, topical: 1% to 2%), aggressive behavior (buccal, intramuscular: 1%), stinging sensation (lips; buccal: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (&le;8%), crusted skin (nasal scab; intranasal: 4% to 6%), excoriation (nasal; intranasal: &le;6%), contact dermatitis (topical, transdermal: 2% to 4%), bulla (application site; transdermal: &lt;3%), skin rash (&lt;3%), pruritus (&le;2%), xeroderma (topical: &le;2%), erythema (topical: &ge;1%), hyperhidrosis (intramuscular: 1%), alopecia (topical: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased HDL cholesterol (topical: &le;6%), hyperlipidemia (&le;6%), hypokalemia (topical: &le;6%), increased serum triglycerides (&le;6%), increased thyroid stimulating hormone level (intranasal: &le;6%), increased plasma estradiol concentration (intramuscular: 3%), decreased libido (&le;3%), gynecomastia (&le;3%), hot flash (intramuscular, topical: 1%), weight gain (intramuscular: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gingivitis (buccal: &le;9%), mouth irritation (buccal: &le;9%), decreased appetite (intranasal: &le;6%), nausea (&le;6%), diarrhea (&le;4%), gingival pain (buccal: 3%; includes gingival tenderness), dysgeusia (&lt;3%), gastroesophageal reflux disease (transdermal: &lt;3%), gastrointestinal hemorrhage (transdermal: &lt;3%), increased appetite (topical, transdermal: &lt;3%), gingival swelling (buccal: 2%), toothache (buccal: &le;1%), oral mucosa changes (buccal; includes buccal mucosa roughening and gum blister)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Testicular atrophy (intranasal, topical: &le;6%), prostatic disease (topical, transdermal: 3% to 5%), hypogonadism (intramuscular: 3%), mastalgia (topical: &le;3%; buccal: 1%), prostatitis (transdermal: &le;3%), dysuria (intramuscular, transdermal: &lt;3%), hematuria (transdermal: &lt;3%), impotence (transdermal: &lt;3%), pelvic pain (transdermal: &lt;3%), urinary incontinence (transdermal: &lt;3%), urinary tract infection (transdermal: &lt;3%), testicular disease (including testicular tenderness and non-palpable testes: topical: 2%), urinary frequency (topical: &le;2%), breast hypertrophy (buccal: 1%), difficulty in micturition (buccal, topical: 1%), ejaculatory disorder (intramuscular: 1%), prostate induration (intramuscular: 1%), spontaneous erections (topical: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (topical: &le;6%), abnormal hepatic function tests (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Increased hematocrit (topical: &le;6%; buccal, intramuscular: 1%), anemia (topical: 3%), polycythemia (&le;3%), prostate carcinoma (topical, transdermal: &lt;3%), increased hemoglobin (intramuscular, topical: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema (topical, transdermal: &le;7%), application site vesicles (transdermal: 6%), application site reaction (topical: &le;6%), pain at injection site (intramuscular: 5%), application site induration: transdermal: 3%), application site irritation (transdermal: &lt;3%), application site rash (transdermal: &lt;3%), local skin exfoliation (transdermal; application site: &lt;3%), application site burning (topical, transdermal: 1% to 3%), application site edema (topical: &ge;1%), erythema at injection site (intramuscular: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (transdermal: 6%), myalgia (intramuscular, intranasal: &le;6%), limb pain (intranasal, topical: &le;4%), weakness (topical: &le;3%), abnormal bone growth (accelerated; transdermal: &lt;3%), hemarthrosis (transdermal: &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (topical: &le;6%), polyuria (transdermal: &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (intranasal: 4% to 9%; topical: &ge;1%), rhinorrhea (intranasal: 4% to 8%), epistaxis (intranasal: 4% to 7%), nasal discomfort (intranasal: 4% to 6%), bronchitis (intranasal: 4%), upper respiratory tract infection (intranasal: 4%), dry nose (intranasal: &le;4%), nasal congestion (intranasal: &le;4%), sinusitis (intramuscular, intranasal: &le;4%), cough (intramuscular, intranasal: &lt;3%), nasal mucosa swelling (buccal: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Exacerbation of hypertension (buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hostility (topical)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (buccal), gum line erosion (buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic adenoma (intramuscular; long-term testosterone enanthate therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abscess at injection site, allergic dermatitis, altered hormone level (fluctuating testosterone levels), amnesia, anaphylactoid reaction, anaphylactic shock, anaphylaxis, androgenetic alopecia, angina pectoris, angioedema, asthma, azoospermia, bitter taste, breast induration, calcium retention, cardiac failure, cerebral infarction, cerebrovascular accident, cerebrovascular insufficiency, change in HDL, chest pain, cholestatic jaundice, chronic obstructive pulmonary disease, circulatory shock, clotting factors suppression (factors II, V, VII, X), coronary artery disease, coronary occlusion, decreased plasma testosterone, decreased thyroxine binding globulin, deep vein thrombosis, device expulsion (pellet extrusion), diabetes mellitus, diaphoresis, discomfort at injection site, dizziness, dyspnea, edema, electrolyte disturbance (calcium, nitrogen, phosphorus, potassium, sodium), erectile dysfunction, fluid retention, flu-like symptoms, frequent erections, genitourinary infection (prostate), gingival erythema, hair discoloration, hearing loss (sudden), hematoma at injection site, hepatic neoplasm, hepatocellular neoplasm, hepatotoxicity (idiosyncratic; Chalasani 2014), hirsutism, hyperchloremia, hypernatremia, hyperparathyroidism, hypersensitivity angiitis, hypersensitivity reaction, hyperventilation, increased gamma-glutamyl transferase, increased intraocular pressure, increased libido, increased serum ALT, increased serum AST, increased serum prolactin, increased serum transaminases, increased testosterone level, infection, injection site reaction, inorganic phosphate retention, irritation at injection site, Korsakoff psychosis (nonalcoholic), lip edema, localized infection (abscess, cellulitis), malaise, malignant neoplasm of prostate, migraine, musculoskeletal chest pain, musculoskeletal pain, myocardial infarction, nipple tenderness (sensitivity), oligospermia (may occur at high dosages), oral inflammation, oral mucosa ulcer, orgasm disturbance (male), osteoporosis, papular rash, peliosis hepatitis, peripheral edema, pharyngeal edema, pharyngolaryngeal pain, pollakiuria, potassium retention, priapism, prolonged partial thromboplastin time, prolonged prothrombin time, prostatic intraepithelial neoplasia, pulmonary embolism (including pulmonary oil microembolism), renal colic, renal function abnormality, renal pain, respiratory distress, restlessness, reversible ischemic neurological deficit, rhinitis, sleep apnea, sleep disorder, snoring, sodium retention, spermatocele, syncope, stomatitis, systemic lupus erythematosus, tachycardia, testicular pain, thrombocytopenia, thromboembolism, thrombosis, tinnitus, transient ischemic attacks, upper abdominal pain, urination disorder, urolithiasis, vasodilatation, venous insufficiency, venous thromboembolism, vitreous detachment, voice disorder, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225977\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Breast cancer (males); prostate cancer (known or suspected); pregnant women or women who may become pregnant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Vogelxo: Additional contraindication: Breast-feeding women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Andriol [Canadian product]: Additional contraindications: Hypersensitivity to any component of the formulation; use in women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aveed: Additional contraindications: Hypersensitivity to testosterone undecanoate, castor oil, benzyl benzoate; breast-feeding women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Depo-Testosterone: Additional contraindications: Hypersensitivity to testosterone cypionate, serious cardiac, hepatic, or renal disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Testosterone enanthate: Additional contraindications: Hypersensitivity to any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for androgens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225958\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: Long term use (&gt;10 years) of parenteral testosterone for male hypogonadism may increase the risk of breast cancer (Medras 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Available studies are inconclusive regarding the risk of developing major adverse cardiovascular events (MACE) such as nonfatal MI, stroke, or cardiovascular death following testosterone use. Some studies have suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy (Basaria 2010; Finkle 2014; Vigen 2013), although the overall evidence does not demonstrate an increased or decreased cardiovascular risk (Endocrine Society [Bhasin 2010]; Corona 2014; Morgentaler 2015). According to the FDA, prescribe testosterone therapy only for men with low testosterone levels caused by certain medical conditions (eg, disorders of the testicles, pituitary gland, brain) and confirmed by laboratory tests (FDA Drug Safety Communication 2015).  However, in a position statement issued by the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE), they recommend that after a thorough diagnostic work-up, testosterone replacement should be guided by signs and symptoms and testosterone concentrations rather than the underlying cause (AACE/ACE [Goodman 2015]). The Endocrine Society suggests it may be prudent to avoid testosterone therapy in men who have experienced a cardiovascular event (eg, MI, stroke, acute coronary syndrome) in the past six months (The Endocrine Society 2014). Evaluate patients for cardiovascular risk factors prior to initiating therapy and monitor closely during therapy for cardiovascular events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: May alter serum lipid profile; use caution with history of MI or coronary artery disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gynecomastia: May cause gynecomastia, which may persist in patients treated for hypogonadism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Prolonged use of high doses of androgens has been associated with serious hepatic effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, jaundice). Prolonged use of intramuscular testosterone enanthate has been associated with multiple hepatic adenomas. Discontinue therapy if signs or symptoms of hepatic dysfunction (such as jaundice) develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: May cause hypercalcemia in patients with prolonged immobilization or cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligospermia: Large doses may suppress spermatogenesis; oligospermia may occur. Discontinue therapy if this occurs, if restarted, a lower dose should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polycythemia: May increase hematocrit requiring dose adjustment or discontinuation. Withhold initial treatment in patients with hematocrit &gt;50%.  Discontinue therapy if hematocrit exceeds 54%; may reinitiate at lower dose (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Priapism or excessive sexual stimulation may occur; discontinue therapy if this occurs, if restarted, a lower dose should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostate cancer: May increase the risk of prostate cancer. Withhold therapy pending urological evaluation in patients with palpable prostate nodule or induration, PSA &gt;4 ng/mL, or PSA &gt;3 ng/mL in men at high risk of prostate cancer (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Venous thromboembolism:   Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE.   Discontinue therapy if a venous thromboembolism is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benign prostatic hyperplasia (BPH): Androgens may worsen BPH; do not use in patients with severe lower urinary tract symptoms [(AUA)/International Prostate Symptom Score (IPSS) &gt; 19] (Endocrine Society [Bhasin 2010]). Discontinue therapy if urethral obstruction develops in patients with BPH (use lower dose if restarted).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases that may be exacerbated by fluid retention, including cardiac impairment; testosterone may cause fluid retention. Treatment of androgen deficiency syndromes is not recommended for men with uncontrolled or poorly controlled heart failure (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; testosterone may cause fluid retention; testosterone cypionate is contraindicated in serious hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; testosterone may cause fluid retention; testosterone cypionate is contraindicated in serious renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep apnea: May potentiate sleep apnea in some male patients, especially those with risk factors (eg, obesity or chronic lung disease). Withhold initial treatment in patients with untreated obstructive sleep apnea (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Geriatric patients may be at greater risk for prostatic hyperplasia, prostate cancer, fluid retention, and transaminase elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May accelerate bone maturation (without producing compensatory gain in linear growth) and premature closure of the epiphyses in children; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers. Use with caution in males with delayed puberty.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women: During treatment for metastatic breast cancer, women should be monitored for signs of virilization; discontinue if mild virilization is present to prevent irreversible symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Castor oil: Some products may contain castor oil.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gel, intranasal: Use of the intranasal gel is not recommended in patients with sinus disease, mucosal inflammatory disorders (eg, Sjogren syndrome), or with a history of nasal disorders, nasal or sinus surgery, nasal fracture within the previous 6 months, or nasal fracture that caused a deviated anterior nasal septum. Safety and efficacy have not been established in males with a BMI &gt;35 kg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gel, topical: Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure; these products are not interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Testosterone cypionate should not be used interchangeably with testosterone propionate due to differences in duration of action.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary oil microembolism: Testosterone undecanoate injection: <b>[US Boxed Warning]: Serious pulmonary oil microembolism (POME) reactions and anaphylaxis have been reported with testosterone undecanoate injection. Reactions include anaphylaxis, chest pain, urge to cough, dizziness, dyspnea, throat tightening, and syncope; may be life threatening. Reactions may occur after any injection during the course of therapy, including the first dose. Patients must be monitored for 30 minutes after injection. Due to the risk of serious POME reactions, Aveed is only available through the Aveed REMS program.</b> To minimize risk of adverse reactions, inject deeply into gluteal muscle. Rare reports of reactions involving urge to cough, coughing fits, and respiratory distress immediately after the injection of testosterone enanthate (an oil-based depot preparation) have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Solution: Axiron is not interchangeable with other topical testosterone products. Use in males with BMI &gt;35 kg/m<sup>2</sup> has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: Anabolic steroids may be abused, typically at doses higher than recommended and in combination with other anabolic androgenic steroids; abuse may be associated with serious cardiovascular and psychiatric adverse reactions. Inform patients of the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids; if abuse is suspected, check serum testosterone levels (testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives). Consider the possibility of abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dependence: Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented; however dependence may occur when used outside of approved dosage/indications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary exposure: Testosterone may be transferred to another person following skin-to-skin contact with the application site. <b>[US Boxed Warning]: Virilization in children has been reported following contact with unwashed or unclothed application sites of men using topical testosterone. Patients should strictly adhere to instructions for use in order to prevent secondary exposure.</b> Children and women should avoid contact with application sites of men using topical products. Symptoms of virilization generally regress following removal of exposure; however, in some children, enlarged genitalia and bone age did not fully return to age appropriate normal. Signs of inappropriate virilization in women or children following secondary exposure to topical testosterone should be brought to the attention of a healthcare provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226024\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225962\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9981&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Androgens may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Testosterone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225965\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225980\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated in pregnant women or women who may become pregnant. Exposure to a fetus may cause virilization of varying degrees. Because of the potential for secondary exposure, all children and women should avoid skin-to-skin contact to areas where testosterone has been applied topically on another person.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some products contain benzyl alcohol, which can cross the placenta.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Large doses of testosterone may suppress spermatogenesis. Treatment of hypogonadotropic hypogonadism is not recommended for men desiring fertility (Endocrine Society [Bhasin 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4472757\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Testosterone is excreted in breast milk. Most products are contraindicated while breast-feeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Distribution of testosterone in breast milk was evaluated following use of the subcutaneous pellet in a nursing woman. Prior to therapy, milk concentrations of testosterone were 96 pg/mL. Following SubQ implantation of the 100 mg pellet, milk samples ranged from 88 pg/mL (day 2) to 100 pg/mL (day 7 [morning]). Reported maternal serum samples ranged from &lt;100 pg/mL (baseline), 2830 pg/mL (day 2), and 1,480 pg/mL (day 7 [morning]). Adverse events were not observed in the nursing male infant after 7 months of continuous maternal therapy (Glaser 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Because of the potential for secondary exposure, all children and women should avoid skin-to-skin contact to areas where testosterone has been applied topically on another person.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">High levels of endogenous maternal testosterone, such as those caused by certain ovarian cysts, suppress milk production. Maternal serum testosterone levels generally fall following pregnancy and return to normal once breast-feeding is stopped (Betzold 2004; Hoover 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225967\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to treatment initiation: Confirm hypogonadism by measuring morning serum testosterone on at least 2 separate days.  Liver function tests, lipid panel, hemoglobin and hematocrit (withhold initial treatment with hematocrit &gt;50%) (Endocrine Society [Bhasin 2010]).  PSA and prostate exam in men &gt;40 years of age with baseline PSA &gt;0.6 ng/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">During treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Liver function tests, lipid panel, hemoglobin and hematocrit (at 3 to 6 months then annually); discontinue therapy if hematocrit exceeds 54% (Endocrine Society [Bhasin 2010]). Monitor urine and serum calcium and signs of virilization in women treated for breast cancer. Serum glucose (may be decreased by testosterone, monitor patients with diabetes). Evaluate males for response to treatment and adverse events 3 to 6 months after initiation and then annually; monitor for cardiovascular events closely during therapy. Monitor serum testosterone 3 to 6 months after initial dose titration (if applicable) then annually.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bone mineral density:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prepubertal children: Radiologic examination of wrist and hand every 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypogonadal men with osteoporosis or low trauma fracture: Monitor after 1 to 2 years of therapy (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PSA: In men &gt;40 years of age with baseline PSA &gt;0.6 ng/mL, PSA and prostate exam at 3 to 6 months, then as based on current guidelines. Withhold treatment pending urological evaluation in patients with palpable prostate nodule or induration or PSA &gt;4 ng/mL or if PSA &gt;3 ng/mL in men at high risk of prostate cancer (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Formulation-specific monitoring:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AndroGel 1%: Morning serum testosterone levels ~14 days after start of therapy or dose adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AndroGel 1.62%: Morning serum testosterone levels after 14 and 28 days of starting therapy or dose adjustments and periodically thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Androderm: Morning serum testosterone levels (following application the previous evening) ~14 days after start of therapy or dose adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aveed: Monitor for 30 minutes after injection; appropriate treatment should be available in the event of a serious POME reaction or anaphylaxis. Measure testosterone level just prior to each subsequent injection and adjust dosing interval to maintain serum testosterone in mid-normal range (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Axiron: Serum testosterone levels can be measured 2 to 8 hours after application and after 14 days of starting therapy or dose adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fortesta: Serum testosterone levels can be measured 2 hours after application and after 14 and 35 days of starting therapy or dose adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Natesto: Measure total serum testosterone periodically, beginning 1 month after initiating therapy. Discontinue therapy if the total serum testosterone consistently exceeds 1,050 ng/dL. If total serum testosterone is consistently &lt;300 ng/dL consider an alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Striant: Examine application area of gums; total serum testosterone 4 to 12 weeks after initiating treatment, prior to morning dose. Discontinue therapy if the total serum testosterone are consistently outside of the normal range (300 to 1,050 ng/dL).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Testim: Morning serum testosterone levels ~14 days after start of therapy or dose adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Testopel: Measure at the end of the dosing interval (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Testosterone cypionate injection: Measure testosterone level midway between injections. Adjust dose or frequency if testosterone concentration is &lt;400 ng/dL or &gt;700 ng/dL (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Testosterone enanthate injection: Measure testosterone level midway between injections. Adjust dose or frequency if testosterone concentration is &lt;400 ng/dL or &gt;700 ng/dL (Endocrine Society [Bhasin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vogelxo: Measure serum testosterone ~14 days after initiation of therapy, in the morning, prior to application.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225971\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">The lower limit of the normal free testosterone range varies by laboratory (Endocrine Society [Bhasin 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225957\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Principal endogenous androgen responsible for promoting the growth and development of the male sex organs and maintaining secondary sex characteristics in androgen-deficient males</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225976\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (route and ester dependent): IM: Cypionate and enanthate esters: 2 to 4 weeks; Undecanoate: 10 weeks; Transdermal gel: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Transdermal gel: ~10% of applied dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 98%; bound to sex hormone-binding globulin (40%) and albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; forms metabolites, including dihydrotestosterone (DHT) and estradiol (both active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral capsule [Canadian product]: ~7%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Variable: 10 to 100 minutes; Testosterone cypionate: ~8 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM (undecanoate): 7 days (median; range: 4 to 42 days); Intranasal: ~40 minutes; Transdermal system: 8 hours (range: 4 to 12 hours); Buccal system: 10 to 12 hours; Oral capsule [Canadian product]: 4 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (90%; oral capsule [Canadian product]: 45% to 48%); feces (6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225979\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (AndroGel Pump Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20.25 MG/ACT (1.62%) (75 g): $745.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (AndroGel Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20.25 MG/1.25GM (1.62%) (1.25 g): $24.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 MG/2.5GM (1%) (2.5 g): $24.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40.5 MG/2.5GM (1.62%) (2.5 g): $25.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 MG/5GM (1%) (5 g): $25.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Fortesta Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 MG/ACT (2%) (60 g): $497.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Natesto Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5.5 mg/ACT (7.32 g): $286.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Testim Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 MG/5GM (1%) (5 g): $23.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Testosterone Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 MG/ACT (2%) (60 g): $409.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 MG/ACT (1%) (75 g): $154.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 MG/2.5GM (1%) (2.5 g): $10.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 MG/5GM (1%) (5 g): $10.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Vogelxo Pump Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 MG/ACT (1%) (75 g): $267.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Vogelxo Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 MG/5GM (1%) (5 g): $17.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Misc</b> (Striant Buccal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (60): $869.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Androderm Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/24 hrs (1): $11.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/24 hrs (1): $22.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pellet</b> (Testopel Implant)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (10): $1,125.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aveed Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg/3 mL (3 mL): $1,220.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Depo-Testosterone Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (10 mL): $88.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (1 mL): $28.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Testosterone Cypionate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (10 mL): $59.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (10 mL): $101.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Testosterone Enanthate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (5 mL): $84.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Testosterone Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/ACT (90 mL): $619.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225982\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Androderm (AU, BB, NZ);</li>\n      <li>AndroForte (AU);</li>\n      <li>Androgel (AE, BE, BH, CU, CZ, EE, FR, HK, HN, HU, IE, IT, KW, MY, NL, PL, QA, RU, SA, SG, TH, TW, VN);</li>\n      <li>Andropatch (GR);</li>\n      <li>Aquaviron (IN);</li>\n      <li>Axiron (AU);</li>\n      <li>Depo-Test (TH);</li>\n      <li>Depo-Testosterone (BB, ZA);</li>\n      <li>Intrinsa Patch (FR, IE);</li>\n      <li>Itnogen (ES);</li>\n      <li>Jenasteron (KR);</li>\n      <li>Lowtiyel (MX);</li>\n      <li>Nebido (HU, LV);</li>\n      <li>Omnadren (PL);</li>\n      <li>Primoniat Depot (CL);</li>\n      <li>Primoteston Depot (AU, BF, BJ, CI, EC, ET, GH, GM, GN, KE, KR, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Primotestone Depot (AE, KW);</li>\n      <li>Proviron Depot (VE);</li>\n      <li>Reandron (ES);</li>\n      <li>Sustanon (EG, JO, KW, SA);</li>\n      <li>Testex (ES);</li>\n      <li>Testim (BE, DK, ES, GB, HU, IE, IS, LU, LV, MT, NO, PL, SI, SK);</li>\n      <li>Testocaps (LU);</li>\n      <li>Testoderm (AT);</li>\n      <li>Testogel (BG, DK, IE, IS, TR);</li>\n      <li>Testom (RO);</li>\n      <li>Testopatch (FR);</li>\n      <li>Testosteron Ferring (AT);</li>\n      <li>Testosteronum propionicum (PL);</li>\n      <li>Testotop (LU);</li>\n      <li>Testoviron (BH, CY, JO, LB, PK, SI, TR);</li>\n      <li>Testoviron Depot (LK, QA, SA);</li>\n      <li>Testoviron-Depot (AR, CH, CO, DE, DK, IL, PE, PT, PY, SE, UY);</li>\n      <li>Tostran (GB, IE);</li>\n      <li>Tostrex (ID);</li>\n      <li>Tostrex Gel (KR);</li>\n      <li>Virormone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Vivrone (PH);</li>\n      <li>Y45 (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andriol (testosterone undecanoate) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Androderm (testosterone transdermal system) [prescribing information]. Irvine, CA: Allergen USA, Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AndroGel 1% (testosterone) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AndroGel 1.62% (testosterone) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aveed (testosterone undecanoate) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Axiron (testosterone) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basaria S, Coviello AD, Travison TG. Adverse events associated with testosterone administration. <i>N Engl J Med</i>. 2010;363(2):109-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/20592293/pubmed\" target=\"_blank\" id=\"20592293\">20592293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betzold CM, Hoover KL, Snyder CL. Delayed lactogenesis II: a comparison of four cases.<i> J Midwifery Womens Health</i>. 2004;49(2):132-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/15010666/pubmed\" target=\"_blank\" id=\"15010666\">15010666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhasin S, Cunningham GR, Hayes FJ, et al, &ldquo;Testosterone Therapy In Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2010, 95(6):2536-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/20525905/pubmed\" target=\"_blank\" id=\"20525905\">20525905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. <i>Expert Opin Drug Saf</i>. 2014;13(10):1327-1351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/25139126/pubmed\" target=\"_blank\" id=\"25139126\">25139126</a>]</span><span class=\"doi\">10.1517/14740338.2014.950653</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delatestryl (testosterone enanthate) [prescribing information]. Malvern, PA: Endo Pharmaceuticals; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depo-Testosterone (testosterone cypionate) [prescribing information]. New York, NY: Pfizer; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Endocrine Society news release. Endocrine Society Calls for Large-Scale Studies to Evaluate Testosterone Therapy Risks. 2014. Endocrine Society website. https://www.endocrine.org/news-room/press-release-archives/2014/endocrine-society-calls-for-large-scale-studies-to-evaluate-testosterone-therapy-risks. Accessed February 5, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Drug Safety Communications. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Food and Drug Administration website. <a href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM383909.pdf%20\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM383909.pdf</a>. Published January 31, 2014. Accessed February 5, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. <i>PLoS One</i>. 2014;9(1):e85805.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/24489673/pubmed\" target=\"_blank\" id=\"24489673\">24489673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortesta (testosterone) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glaser RL, Newman M, Parsons M et al. Safety of maternal testosterone therapy during breast feeding. <i>Int J Pharm Compound</i>. 2009;13:314-317.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology (ACE) position statement on the association of testosterone and cardiovascular risk. <i>Endocr Pract</i>. 2015;21(9):1066-1073.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/26355962/pubmed\" target=\"_blank\" id=\"26355962\">26355962</a>]</span><span class=\"doi\">10.4158/EP14434.PS</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoover KL, Barbalinardo LH, Platia MP. Delayed lactogenesis II secondary to gestational ovarian theca lutein cysts in two normal singleton pregnancies.<i> J Hum Lact</i>. 2002;18(3):264-268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/12192962/pubmed\" target=\"_blank\" id=\"12192962\">12192962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Medras M, Filus A, Jozkow P, Wiowski J, Sicinska-Werner T. Breast cancer and long-term horonal treatment of male hypogonadism. <i>Breast Cancer Res Treat</i>. 2006; 96(3): 263-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/16418796/pubmed\" target=\"_blank\" id=\"16418796\">16418796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. <i>Mayo Clin Proc</i>. 2015;90(2):224-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/25636998/pubmed\" target=\"_blank\" id=\"25636998\">25636998</a>]</span><span class=\"doi\">10.1016/j.mayocp.2014.10.011</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Natesto (testosterone nasal gel) [prescribing information]. Englewood, CO: Aytu BioScience, Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petak SM, Nankin HR, Spark RF, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients &minus; 2002 Update,&rdquo; <i>Endocr Pract</i>, 2002, 8(6):440-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/15260010/pubmed\" target=\"_blank\" id=\"15260010\">15260010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Striant (testosterone) [prescribing information]. Malvern, PA: Actient Pharmaceuticals LLC; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Testim (testosterone) [prescribing information]. Malvern, PA: Auxilium Pharmaceuticals; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Testosterone enanthate injection [prescribing information]. Eatontown,NJ: West-Ward Pharmaceutical; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Testosterone Gel [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Testopel (testosterone) [prescribing information]. Malvern, PA: Auxilium Pharmaceuticals, Inc.; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vigen R, O'Donnell CI, Bar&oacute;n AE. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels [published correction appears in <i>JAMA</i>. 2014;311(9):967]. <i>JAMA</i>. 2013;310(17):1829-1836.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/24193080/pubmed\" target=\"_blank\" id=\"24193080\">24193080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vogelxo (testosterone) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(10):3489-3510. doi: 10.1210/jc.2014-2260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/testosterone-drug-information/abstract-text/25279570/pubmed\" target=\"_blank\" id=\"25279570\">25279570</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9981 Version 249.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9632723\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F225996\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F225997\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F226028\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F226000\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F226019\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F226001\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F11386628\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F226002\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F225970\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F225954\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F45040041\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950983\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F226030\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9632804\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F225974\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132740\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F225973\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F226035\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F225961\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F225977\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F225958\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F226024\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F225962\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F225965\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F225980\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4472757\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F225967\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F225971\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F225957\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F225976\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F225979\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F225982\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9981|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=testosterone-patient-drug-information\" class=\"drug drug_patient\">Testosterone: Patient drug information</a></li><li><a href=\"topic.htm?path=testosterone-pediatric-drug-information\" class=\"drug drug_pediatric\">Testosterone: Pediatric drug information</a></li></ul></div></div>","javascript":null}